ArticleslgStudy

science

IOMAI

IOMAI is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand IOMAI rather than just read about it. In short: IOMAI was a Biotech company founded in 1997 by Gregory Glenn M.D. of the Walter Reed Army Institute of Research and Dean Lewis, a World Bank employee. The company was the first to develop the concept of transcutaneous immunization, delivery of vaccines to the skin using a patch or similar method.

Key takeaways

  • IOMAI belongs to science; place it in that map before memorising details.
  • Learn the definition first, then one example that makes the definition concrete.
  • Connect IOMAI to a quantity you can measure, compute or draw — that is where exam questions come from.
  • Reproduce the core statement of IOMAI from memory before moving on to harder problems.

Reference excerpt

IOMAI was a Biotech company founded in 1997 by Gregory Glenn M.D. of the Walter Reed Army Institute of Research and Dean Lewis, a World Bank employee. The company was the first to develop the concept of transcutaneous immunization, delivery of vaccines to the skin using a patch or similar method. This provided a means to stimulate robust immune responses safely as the skin patch-based immunization targeted Langerhans cells in the skin. The patch technology underwent extensive evaluation in the context of a traveler's diarrhea vaccine which entered Phase 3 pivotal trials in 2009. IOMAI was acquired by Intercell in 2008 and the technology was the subject of a development license to GSK in 2009. Dr. Glenn pioneered needle free delivery to the skin and spawned general interest in skin-targeting vaccine technologies, including intradermal delivery and the use of the heat labile toxin as an adjuvant and the adjuvant patch.

See also Transdermal patch

References

Frech, SA; Dupont, HL; Bourgeois, AL; McKenzie, R; Belkind-Gerson, J; Figueroa, JF; Okhuysen, PC; Guerrero, NH; Martinez-Sandoval, FG; Meléndez-Romero, JH; Jiang, ZD; Asturias, EJ; Halpern, J; Torres, OR; Hoffman, AS; Villar, CP; Kassem, RN; Flyer, DC; Andersen, BH; Kazempour, K; Breisch, SA; Glenn, GM (Jun 2008). "Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial". Lancet. 371 (9629): 2019–25. doi:10.1016/s0140-6736(08)60839-9. PMID 18554712. S2CID 32784525. McKenzie, R; Bourgeois, AL; Frech, SA; Flyer, DC; Bloom, A; Kazempour, K; Glenn, GM (May 2007). "Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study". Vaccine. 25 (18): 3684–91. doi:10.1016/j.vaccine.2007.01.043. PMID 17313998. Glenn, GM; Villar, CP; Flyer, DC; Bourgeois, AL; McKenzie, R; Lavker, RM; Frech, SA (May 2007). "Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum". Infect Immun. 75 (5): 2163–70. doi:10.1128/iai.01740-06. PMC 1865773. PMID 17261601. Glenn, GM; Thomas, DN; Poffenberger, KL; Flyer, DC; Ellingsworth, LR; Andersen, BH; Frech, SA (Dec 2009). "Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch". Vaccine. 27 (Suppl 6): G60–6. doi:10.1016/j.vaccine.2009.10.031. PMID 20006142. Kenney, RT; Frech, SA; Muenz, LR; Villar, CP; Glenn, GM (Nov 2004). "Dose sparing with intradermal injection of influenza vaccine". N Engl J Med. 351 (22): 2295–301. doi:10.1056/nejmoa043540. PMID 15525714.

Worked examples

Example 1 — a first encounter with IOMAI

Start with the simplest possible case. Write down what IOMAI claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to IOMAI before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about IOMAI ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of IOMAI

In research
IOMAI appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry
Engineering practice reuses IOMAI in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom
IOMAI is common in secondary-school and first-year university syllabi. It links to neighbouring topics Biotechnology companies of the United States, Biotechnology stubs, United States company stubs, so understanding it makes those chapters shorter.
In everyday life
Look for IOMAI outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study IOMAI in 20 minutes

  1. Read the reference excerpt below once, without taking notes.
  2. Close the page and write down what IOMAI means in your own words.
  3. Compare your version with the excerpt and mark what you missed.
  4. Work through the three examples above with pen and paper.
  5. Explain IOMAI out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is IOMAI in simple terms?

IOMAI was a Biotech company founded in 1997 by Gregory Glenn M.D. of the Walter Reed Army Institute of Research and Dean Lewis, a World Bank employee. The company was the first to develop the concept of transcutaneous immunization, delivery of vaccines to the skin using a patch or similar method.

Why does IOMAI matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study IOMAI?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on IOMAI.

Tags

  • Biotechnology companies of the United States
  • Biotechnology stubs
  • United States company stubs

Keep exploring